[KSCI] Korea Science Citation Index Service

http://dx.doi.org/10.5713/ajas.2010.90637

Therapy of Diabetes Mellitus Using Experimental Animal Models

Min, T.S. (National Research Foundation of Korea)
Park, Soo Hyun (National Research Foundation of Korea)

Publication Information

Asian-Australasian Journal of Animal Sciences / v.23, no.5, 2010 , pp. 672-679 More about this Journal

Abstract

Diabetes mellitus is a worldwide epidemic with high mortality. As concern over this disease rises, the number and value of research grants awarded by the National Research Foundation of Korea (NRF) have increased. Diabetes mellitus is classified into two groups. Type 1 diabetes requires insulin treatment, whereas type 2 diabetes, which is characterized by insulin resistance, can be treated using a variety of therapeutic approaches. Hyperglycemia is thought to be a primary factor in the onset of diabetes, although hyperlipidemia also plays a role. The major organs active in the regulation of blood glucose are the pancreas, liver, skeletal muscle, adipose tissue, intestine, and kidney. Diabetic complications are generally classified as macrovascular (e.g., stroke and heart disease) or microvascular (i.e., diabetic neuropathy, nephropathy, and retinopathy). Several animal models of diabetes have been used to develop oral therapeutic agents, including sulfonylureas, biguanides, thiazolidinediones, acarbose, and miglitol, for both type 1 and type 2 diseases. This review provides an overview of diabetes mellitus, describes oral therapeutic agents for diabetes and their targets, and discusses new developments in diabetic drug research.

Keywords

Diabetes; Diabetic Complications; Experimental Animal Models; Therapeutic Agents;

Citations & Related Records

Times Cited By Web Of Science : 0 (Related Records In Web of Science)
Times Cited By SCOPUS : 0

Reference

1	Shafrir, E. 1992. Animal models of non insulin dependent diabetes. Diabetes Metab. Rev. 8:179-208 DOI PUBMED ScienceOn
2	Srinivasan, K., B. Viswanad, L. Asrat, C. L. Kaul and P. Ramarao. 2005. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol. Res. 52:313-320 DOI ScienceOn
3	Ashcroft, F. M. and P. Rorsman. 1990. ATP-sensitive K+ channels: a link between B-cell metabolism and insulin secretion. Biochem. Soc. Trans. 18:109-111 PUBMED ScienceOn
4	Daneman, D. 2009. State of the world's children with diabetes. Pediatr Diabetes 10:120-126 DOI PUBMED ScienceOn
5	Elnasri, H. A. and A. M. Ahmed. 2008. Patterns of lipid changes among type 2 diabetes patients in Sudan. East Mediterr. Health J. 14:314-324 PUBMED
6	Capeau, J. 2008. Insulin resistance and steatosis in humans. Diabetes. Metab. 34:649-657 DOI PUBMED ScienceOn
7	Dahan, A. and S. G. McAfee. 2009. A proposed role for the psychiatrist in the treatment of adolescents with type I diabetes. Psychiatr. Q. 80:75-85 DOI ScienceOn
8	Davies, M. J. 2002. Insulin secretagogues. Curr. Med. Res. Opin. 18:s22-s30 DOI PUBMED ScienceOn
9	Frojdo, S., H. Vidal and L. Pirola. 2009. Alterations of insulin signaling in type 2 diabetes: a review of the current evidence from humans. Biochim. Biophys. Acta. 1792:83-92 DOI PUBMED ScienceOn
10	Fallucca, F. and P. Pozzilli. 2009. Physical exercise, public health and quality of life in diabetes. Diabetes Metab. Res. Rev. 25:S1-S3 DOI ScienceOn
11	Joshi, S. R. 2003. Metabolic syndrome-emerging clusters of the Indian phenotype. J. Assoc. Physicians India 51:445-446 PUBMED
12	Katsuno, K., Y. Fujimori, Y. Takemura, M. Hiratochi, F. Itoh, Y. Komatsu, H. Fujikura and M. Isaji. 2007. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J. Pharmacol. Exp. Ther. 320:323-330 DOI ScienceOn
13	Khan, A. H. and J. E. Pessin. 2002. Insulin regulation of glucose uptake: a complex interplay of intracellular signalling pathways. Diabetologia 45:1475-1483 DOI ScienceOn
14	Klover, P. J. and R. A. Mooney. 2004. Hepatocytes: critical for glucose homeostasis. Int. J. Biochem. Cell Biol. 36:753-758 DOI ScienceOn
15	Lencioni, C., R. Lupi and S. Del Prato. 2008. Beta-cell failure in type 2 diabetes mellitus. Curr. Diab. Rep. 8:179-184 DOI ScienceOn
16	Phielix, E. and M. Mensink. 2008. Type 2 diabetes mellitus and skeletal muscle metabolic function. Physiol. Behav. 94:252-258 DOI ScienceOn
17	Nakamura, T., T. Funahashi, S. Yamashita, M. Nishida, Y. Nishida, M. Takahashi, K. Hotta, H. Kuriyama, S. Kihara, N. Ohuchi, T. Nishimura, B. I. Kishino, K. Ishikawa, T. Kawamoto, K. Tokunaga, C. Nakagawa, I. Mineo, F. Watanabe, S. Tarui and Y. Matsuzawa. 2001. Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation--double-blind placebo-controlled trial. Diabetes Res. Clin. Pract. 54:181-190 DOI ScienceOn
18	Nolan, C. J. and M. Prentki. 2008. The islet beta-cell: fuel responsive and vulnerable. Trends Endocrinol. Metab. 19:285-291 DOI ScienceOn
19	Olsen, W. A. and I. H. Rosenberg. 1970. Intestinal transport of sugar and amino acids in diabetic rats. J. Clin. Invest. 49:96-105 DOI PUBMED
20	Purnell, J. Q. and C. Weyer. 2003. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat. Endocrinol. 2:33-47 DOI ScienceOn
21	Qin, B., W. Qiu, R. K. Avramoglu and K. Adeli. 2007. Tumor necrosis factor-alpha induces intestinal insulin resistance and stimulates the overproduction of intestinal apolipoprotein B48-containing lipoproteins. Diabetes 56:450-461 DOI ScienceOn
22	Retnakaran, R. and B. Zinman. 2009. Thiazolidinediones and clinical outcomes in type 2 diabetes. Lancet. 373:2088-2090 DOI ScienceOn
23	Roden, M., K. F. Petersen and G. I. Shulman. 2001. Nuclear magnetic resonance studies of hepatic glucose metabolism in humans. Recent Prog. Horm. Res. 56:219-237 DOI ScienceOn
24	Weltman, N. Y., S. A. Saliba, E. J. Barrett and A. Weltman. 2009. The use of exercise in the management of type 1 and type 2 diabetes. Clin. Sports Med. 28:423-439 DOI ScienceOn
25	Rodriguez, B. L., R. D'Agostino, R. D. Abbott, A. Kagan, C. M. Burchfiel, K. Yano, G. W. Ross, H. Silbershatz, M. W. Higgins, J. Popper, P. A. Wolf and J. D. Curb. 2002. Risk of hospitalized stroke in men enrolled in the Honolulu Heart Program and the Framingham Study: A comparison of incidence and risk factor effects. Stroke 33:230-236 DOI ScienceOn
26	Ron, Y., J. Wainstein, A. Leibovitz, N. Monastirsky, B. Habot, Y. Avni and R. Segal. 2002. The effect of acarbose on the colonic transit time of elderly long-term care patients with type 2 diabetes mellitus. J. Gerontol. A. Biol. Sci. Med. Sci. 57:M111-M114 DOI PUBMED
27	Sicree, R., J. Shaw and P. Zimmet. 2006. Prevalence and projections. In: Diabetes atlas (Ed. D. Gan), 3rd edn. Brussels: International Diabetes Federation, 16-104
28	Wolf, P. A., R. B. D'Agostino, A. J. Belanger and W. B. Kannel. 1991. Probability of stroke: a risk profile from the Framingham Study. Stroke. 22:312-318 DOI PUBMED ScienceOn
29	Yamamoto, H., Y. Uchigata and H. Okamoto. 1981. Streptozotocin and alloxan induce DNA strand breaks and poly(ADP-ribose) synthatase in pancreatic islets. Nature 294:284-286 DOI ScienceOn
30	Ye, Y. L., Z. Zhou, H. J. Zou, Y. Shen, T. F. Xu, J. Tang, H. Z. Yin, M. L. Chen, Y. Leng and J. H. H. Shen. 2009. Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes. Bioorg. Med. Chem. 17:5722-5732 DOI ScienceOn
31	Bjornholm, M. and J. R. Zierath. 2005. Insulin signal transduction in human skeletal muscle: identifying the defects in Type II diabetes. Biochem. Soc. Trans. 33:354-357 DOI ScienceOn
32	Dubuc, P. U. 1976. The development of obesity, hyperinsulinemia, and hyperglycemia in ob/ob mice. Metabolism 25:1567-1574 DOI PUBMED ScienceOn
33	Fawcett, J. and R. Rabkin. 1993. Degradation of insulin by isolated rat renal cortical endosomes. Endocrinology 133:1539-1547 DOI ScienceOn
34	Gallwitz, B. 2008. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. IDrugs. 11:906-917 PUBMED ScienceOn
35	Hallakou, S., L. Doar $\acute{e}$ , F. Foufelle, M. Kergoat, M. Guerre-Millo, M. F. Berthault, I. Dugail, J. Morin, J. Auwerx and P. Ferré. 1997. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 46:1393-1399 DOI ScienceOn
36	Kim, J. H., P. M. Nishina and J. K. Naggert 1998. Genetic models for non insulin dependent diabetes mellitus in rodents. J. Basic Clin. Physiol. Pharmacol. 9:325-345 DOI PUBMED ScienceOn
37	O'Moore-Sullivan, T. M. and J. B. Prins. 2002. Thiazolidinediones and type 2 diabetes: new drugs for an old disease. Med. J. Aust. 176:381-386 PUBMED ScienceOn
38	Qi, L., F. B. Hu and G. Hu. 2008. Genes, environment, and interactions in prevention of type 2 diabetes: a focus on physical activity and lifestyle changes. Curr. Mol. Med. 8:519-532 DOI ScienceOn
39	Tuomilehto, J., D. Rastenyte, P. Jousilahti, C. Sarti and E. Vartiainen. 1996. Diabetes mellitus as a risk factor for death from stroke. Prospective study of the middle-aged Finnish population. Stroke 27:210-215 DOI PUBMED ScienceOn
40	Zierath, J. R., A. Krook and H. Wallberg-Henriksson. 2000. Insulin action and insulin resistance in human skeletal muscle. Diabetologia 43:821-835 DOI ScienceOn
41	Thorens, B. 2001. GLUT2 in pancreatic and extra-pancreatic gluco-detection (review). Mol. Membr. Biol. 18:265-273 DOI PUBMED ScienceOn
42	Haffner, S. M., A. S. Greenberg, W. M. Weston, H. Chen, K. Williams and M. I. Freed. 2002. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106:679-884 DOI ScienceOn
43	Nakasone, H., S. Kako, H. Endo, A. Ito, M. Sato, K. Terasako, S. Okuda, Y. Tanaka, R. Yamazaki, K. Oshima, A. Tanihara, M. Kida, T. Higuchi, K. Izutsu, J. Nishida, A. Urabe, K. Usuki, and Y. Kanda. 2009. Diabetes mellitus is associated with high early-mortality and poor prognosis in patients with autoimmune hemolytic anemia. Hematology 14:361-365 DOI ScienceOn
44	Soldatos, G. and M. E. Cooper. 2008. Diabetic nephropathy: important pathophysiologic mechanisms. Diabetes Res. Clin. Pract. 82:S75-S79 DOI PUBMED ScienceOn
45	Stefansson, E., T. Bek, M. Porta, N. Larsen, J. K. Kristinsson and E. Agardh. 2000. Screening and prevention of diabetic blindness. Acta. Ophthalmol. Scand. 78:374-385 DOI ScienceOn
46	Junod, A., A. E. Lambert, W. Stauffacher and A. E. Renold. 1967. Studies of the diabetogenic action of streptozotocin. Proc. Soc. Exp. Biol. Med. 126:201-205 PUBMED ScienceOn
47	Singh, S., Y. K. Loke and C. D. Furberg. 2007. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 30:2148-2153 DOI ScienceOn
48	Valverde, A. M., D. J. Burks, I. Fabregat, T. L. Fisher, J. Carretero, M. F. White and M. Benito. 2003. Molecular mechanisms of insulin resistance in IRS-2-deficient hepatocytes. Diabetes 52:2239-2248 DOI ScienceOn
49	Zhou, G., R. Myers, Y. Li, Y. Chen, X. Shen, J. Fenyk-Melody, M. Wu, J. Ventre, T. Doebber, N. Fujii, N. Musi, M. F. Hirshman, L. J. Goodyear and D. E. Moller. 2001. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108:1167-1174 DOI PUBMED ScienceOn
50	Reddi, A. S. and R. A. Camerini-Davalos. 1988. Hereditary diabetes in the KK mouse: an overview. Adv. Exp. Med. Biol. 246:7-15 PUBMED
51	Chiasson, J. L., R. G. Josse, R. Gomis, M. Hanefeld, A. Karasik and M. Laakso. 2002. STOP-NIDDM Trail Research Group. 2002. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072-2077 DOI PUBMED ScienceOn
52	Tomkin, G. H. 2008. The intestine as a regulator of cholesterol homeostasis in diabetes. Atheroscler. Suppl. 9:27-32 DOI PUBMED ScienceOn
53	Budhiraja, S. and J. Singh. 2008. Protein kinase C beta inhibitors: a new therapeutic target for diabetic nephropathy and vascular complications. Fundam. Clin. Pharmacol. 22:231-240 DOI ScienceOn
54	Bonner-Weir, S., D. F. Trent, R. N. Honey and G. C. Weir. 1981. Responses of neonatal rat islets to streptozotocin: Limited Bcell regeneration and hyperglycemia. Diabetes 30:64-69 DOI ScienceOn
55	Diabetes Prevention Program Research Group. 2005. Strategies to identify adults at high risk for type 2 diabetes: the Diabetes Prevention Program. Diabetes Care 28:138-144 DOI PUBMED ScienceOn
56	Del, P. S., C. Bianchi and P. Marchetti. 2007. Beta-cell function and anti-diabetic pharmacotherapy. Diabetes Metab. Res. Rev. 23:518-527 DOI ScienceOn
57	Kahn, S. E., S. M. Haffner, M. A. Heise, W. H. Herman, R. R. Holman, N. P. Jones, B. G. Kravitz, J. M. Lachin, M. C. Oneil, B. Zinman and G. Viberti. 2006. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355:2427-2443 DOI ScienceOn
58	Nakhooda, A. F., A. A. Like, C. I. Chappel, F. T. Murray and E. B. Marliss. 1977. The spontaneously diabetic wistar rat. Metabolic and morphological studies. Diabetes 26:100-112 DOI ScienceOn
59	Salman, S., F. Salman, I. Satman, Y. Yilmaz, E. Ozer, A. Sengul, H. O. Demirel, K. Karoidao, N. Dinoao and M. T. Yilmaz. 2001. Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes. Curr. Med. Res. Opin. 16:296-306 DOI ScienceOn
60	Lafontan, M., P. V. Piazza and J. Girard. 2007. Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients. Diabetes Metab. 33:85-95 DOI ScienceOn
61	Crawford, T. N., D. V. Alfaro 3rd, J. B. Kerrison and E. P. Jablon. 2009. Diabetic retinopathy and angiogenesis. Curr. Diabetes Rev. 5:8-13 DOI ScienceOn
62	Adeghate, E., P. Schattner and E. Dunn. 2006. An update on the etiology and epidemiology of diabetes mellitus. Ann. NY. Acad. Sci. 1084:1-29 DOI ScienceOn
63	Fuentes, B., J. Castillo, B. San Jose, R. Leira, J. Serena, J Vivancos, A. D $\acute{a}$ valos, A. G. Nu $\tilde{n}$ ez, J. Egido and E. Díez-Tejedor. 2009. The prognostic value of capillary glucose levels in acute stroke. The GLycemia in Acute Stroke (GLIAS) Study. Stroke. 40:562-568 DOI ScienceOn
64	Musi, N., M. F. Hirshman, J. Nygren, M. Svanfeldt, P. Bavenholm, O. Rooyackers, G. Zhou, J. M. Williamson, O. Ljunqvist, S. Efendic, D. E. Moller, A. Thorell and L. J. Goodyear. 2002. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51:2074-2081 DOI ScienceOn
65	Federico, L. M., M. Naples, D. Taylor and K. Adeli. 2006. Intestinal insulin resistance and aberrant production of apolipoprotein B48 lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia: evidence for activation of protein tyrosine phosphatase-1B, extracellular signal-related kinase, and sterol regulatory element-binding protein-1c in the fructose-fed hamster intestine. Diabetes 55:1316-1326 DOI ScienceOn
66	Sander, G. E., F. E. Wilklow and T. D. Giles. 2004. Heart failure in diabetes mellitus: causal and treatment considerations. Minerva Cardioangiol. 52:491-503 PUBMED ScienceOn
67	Sowers, J. R. 2008. Endocrine functions of adipose tissue: focus on adiponectin. Clin. Cornerstone 9:32-38 DOI PUBMED ScienceOn
68	Makino, S., K. Kunimoto, Y. Munaoko, Y. Mizushima, K. Katagiri and Y. Tochino. 1980. Breeding of a non-obese diabetic strain of mice. Exp. Anim. 29:1-13 PUBMED
69	Ramachandran, A., R. C. Wan Ma and C. Snehalatha. 2010. Diabetes in Asia. Lancet. (in press)
70	Yamauchi, T., J. Kamon, H. Waki, K. Murakami, K. Motojima, K. Komeda, T. Ide, N. Kubota, Y. Terauchi, K. Tobe, H. Miki, A. Tsuchida, Y. Akanuma, R. Nagai, S. Kimura and T. Kadowaki. 2001. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J. Biol. Chem. 276:41245-41254 DOI ScienceOn
71	Ding, S. Y., Z. F. Shen, Y. T. Chen, S. J. Sun, Q. Liu and M. Z. Xie. 2005. Pioglitazone can ameliorate insulin resistance in lowdose streptozotocin and high sucrose-fat diet induced obese rats. Acta. Pharmacol. Sin. 26:575-580 DOI ScienceOn
72	Sacks, D. B. and J. M. McDonald. 1996. The pathogenesis of type II diabetes mellitus. A polygenic disease. Am. J. Clin. Pathol. 105:149-156 PUBMED ScienceOn
73	Unger, R. H. and Y. T. Zhou. 2001. Lipotoxicity of beta-cells in obesity and in other cause of fatty acid spillover. Diabetes 1:S118- S121
74	Van Gaal, L., F. Nobels and I. De Leeuw. 1991. Effects of acarbose on carbohydrate metabolism, electrolytes, minerals and vitamins in fairly well-controlled non-insulin-dependent diabetes mellitus. Z. Gastroenterol. 29:642-644 PUBMED ScienceOn
75	Christensen, M., F. K. Knop, J. J. Holst and T. Vilsboll. 2009. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs. 12:503-513 PUBMED ScienceOn
76	Cleasby, M. E., N. Dzamko, B. D. Hegarty, G. J. Cooney, E. W. Kraegen and J. M. Ye. 2004. Metformin prevents the development of acute lipid-induced insulin resistance in the rat through altered hepatic signaling mechanisms. Diabetes 53:3258-3266 DOI ScienceOn
77	Edelman, S. V. 1998. Type II diabetes mellitus. Adv. Intern. Med. 43:449-500 PUBMED ScienceOn
78	Ito, M., Y. Kondo, A. Nakatani, K. Hayashi and A. Naruse. 2001. Characterization of low dose streptozotocin-induced progressive diabetes in mice. Environ. Toxicol. Pharmacol. 9:71-78 DOI ScienceOn
79	Raddatz, D. and G. Ramadori. 2007. Carbohydrate metabolism and the liver: actual aspects from physiology and disease. Z. Gastroenterol. 45:51-62 DOI ScienceOn
80	Basit, A., M. Z. Hydrie, R. Hakeem, M. Y. Ahmedani and Q. Masood. 2004. Frequency of chronic complications of type II diabetes. J. Coll. Physicians Surg. Pak. 14:79-83 PUBMED
81	Silva, K. C., M. A. Rosales, S. K. Biswas, J. B. Lopes de Faria and J. M. Lopes de Faria. 2009. Diabetic retinal neurodegeneration improved by an angiotensin receptor blocker in a model combining hypertension and diabetes. Diabetes 58:1382-1390 DOI ScienceOn
82	Zucker, L. M. and H. N. Antoniades. 1972. Insulin and obesity in the Zucker genetically obese rat 'fatty'. Endocrinology 90:1320-1330 DOI ScienceOn
83	Taylor, C. and F. D. Hobbs. 2009. Type 2 diabetes, thiazolidinediones, and cardiovascular risk. Br. J. Gen. Pract. 59:520-524 DOI ScienceOn
84	Hyvorinen, M., Q. Qiao, J. Tuomilehto, T. Laatikainen, R. J. Heine, C. D. Stehouwer, K. G. Alberti, K. Pyorol, B. Zethelius and B. Stegmayr 2009. DECODE Study Group. Hyperglycemia and stroke mortality: comparison between fasting and 2-h glucose criteria. Diabetes Care 32:348-354 DOI ScienceOn
85	Mellor, K. M., R. H. Ritchie and L. M. Delbridge. 2010. Reactive oxygen species and insulin resistant cardiomyopathy. Clin. Exp. Pharmacol. Physiol. (in press)
86	Tan, J. T., L. S. Tan, K. S. Chia, S. K. Chew and E. S. Tai. 2008. A family history of type 2 diabetes is associated with glucose intolerance and obesity-related traits with evidence of excess maternal transmission for obesity-related traits in a South East Asian population. Diabetes Res. Clin. Pract. 82:268-275 DOI ScienceOn
87	Turcotte, L. P. and J. S. Fisher. 2008. Skeletal muscle insulin resistance: roles of fatty acid metabolism and exercise. Phys. Ther. 88:1279-1296 DOI PUBMED ScienceOn
88	Prentki, M. 1996. New insights into pancreatic beta-cell metabolic signaling in insulin secretion. Eur. J. Endocrinol. 134:272-286 DOI PUBMED
89	Moore, K. R., T. S. Harwell, J. M. McDowall, S. D. Helgerson, and D. Gohdes. 2003. Three-year prevalence and incidence of diabetes among American Indian youth in Montana and Wyoming, 1999 to 2001. J. Pediatr. 143:368-371 DOI ScienceOn
90	Lanner, J. T., J. D. Bruton, A. Katz and H. Westerblad. 2008. $Ca^{2+}$ and insulin-mediated glucose uptake. Curr. Opin. Pharmacol. 8:339-345 DOI ScienceOn
91	Zucker, T. F. and L. M. Zucker. 1962. Hereditary obesity in the rat associated with high serum fat and cholesterol. Proc. Soc. Exp. Biol. Med. 110:165-171
92	Taplin, C. E. and J. M. Barker. 2008. Autoantibodies in type 1 diabetes. Autoimmunity 41:11-18 DOI ScienceOn
93	Therond, P. 2009. Catabolism of lipoproteins and metabolic syndrome. Curr. Opin. Clin. Nutr. Metab. Care. 12:366-371 DOI PUBMED ScienceOn
94	Kanwar, Y. S., J. Wada, L. Sun, P. Xie, E. I. Wallner, S. Chen, S. Chugh and F. R. Danesh. 2008. Diabetic nephropathy: mechanisms of renal disease progression. Exp. Biol. Med. (Maywood). 233:4-11 DOI ScienceOn
95	Neeli, H., R. Gadi and D. J. Rader. 2009. Managing diabetic dyslipidemia: beyond statin therapy. Curr. Diab. Rep. 9:11-17 DOI ScienceOn
96	Rerup, C. C. 1970. Drugs producing diabetes through damage of the insulin secreting cells. Pharmacol. Rev. 22:485-518 PUBMED ScienceOn
97	Asano, T., M. Fujishiro, A. Kushiyama, Y. Nakatsu, M. Yoneda, H. Kamata and H. Sakoda. 2007. Role of phosphatidylinositol 3-kinase activation on insulin action and its alteration in diabetic conditions. Biol. Pharm. Bull. 30:1610-1616 DOI ScienceOn
98	Bluher, M. 2009. Adipose tissue dysfunction in obesity. Exp. Clin. Endocrinol. Diabetes. 117:241-250 DOI ScienceOn
99	Kawano, K., T. Hirashima, S. Mori, Y. Saitoh, M. Kurosumi and T. Natori. 1992. Spontaneous long-term hyperglycemic rat with diabetic complications, Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 41:1422-1428 DOI ScienceOn
100	Nissen, S. E. and K. Wolski. 2007. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356:2457-2471 DOI ScienceOn